Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | F2 | P00734 | 1/20 | 0.80 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78812 | 1.00 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL2188917 | 0.97 | F10 (0.94) | F10ABCB11F2ST14 | |
| SCHEMBL77782 | 0.92 | F10 (0.86) | F10ABCB11F2ST14 | |
| SCHEMBL79766 | 0.91 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL79087 | 0.91 | F10 (0.85) | F10ABCB11F2ST14 | |
| SCHEMBL78816 | 0.91 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL87121 | 0.90 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL77206 | 0.90 | F10 (1.00) | F10 | |
| Rivaroxaban SCHEMBL3914 | 0.89 | F10 (1.00) | F10ABCB11F2ST14 | |
| Rivaroxaban SCHEMBL7721848 | 0.89 | F10 (1.00) | F10ABCB11F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-8822458-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8530505-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-7767702-B2 | Combinations of oxazolidinones such as rivaroxaban with a platelet aggregation inhibitor such as a clopidogrel for the prophylaxis and/or treatment of thromboembolic disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7576111-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | disclosed |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | disclosed |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007039134-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885ABCB11 337/4885F2 1/4885 |
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | P2RY12, P2RY11, P2RY1 | F10 1174/4885ABCB11 255/4885F2 398/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885ABCB11 337/4885F2 1/4885 |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | OTC, SDHA, SDHB | F10 258/4885ABCB11 162/4885F2 90/4885 |
| US-20080200674-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885ABCB11 337/4885F2 1/4885 |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | SERPINC1, SDHB, F2 | F10 34/4885ABCB11 694/4885F2 3/4885 |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885ABCB11 337/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.